Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CHRM1CHRM2CHRM3CHRM4CHRM5
The experimentally established mechanism targets of Terodiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.93 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.93 |
| ▸ | CACNA1C known ✓ | Q13936 | 2/20 | 0.93 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.93 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.93 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.93 |
| ▸ | CACNA1S known ✓ | Q13698 | 1/20 | 0.93 |
| ▸ | HRH1 | P35367 | 5/20 | 0.93 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.93 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.93 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.93 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.93 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.93 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terodiline SCHEMBL9008621 | 0.96 | HRH1 (1.00) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL78908 | 0.96 | HRH1 (1.00) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL121864 | 0.94 | HRH1 (0.96) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL579993 | 0.94 | HRH1 (0.96) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL8149719 | 0.91 | HRH1 (0.89) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9008867 | 0.86 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9107533 | 0.86 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9008606 | 0.86 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9008774 | 0.86 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9108716 | 0.86 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 632 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066037-A1 | CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-02-29 | — | — | US | disclosed |
| CN-116194114-A | Cathepsin inhibitors for preventing or treating viral infections | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-4125919-A1 | CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-02-08 | — | — | EP | disclosed |
| US-11555040-B2 | Oxepinopyrazole derivatives as inhibitors of P13-kinase activity | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-01-17 | — | — | US | disclosed |
| CN-110785420-B | Oxazepin derivatives as inhibitors of PI 3-kinase activity | 葛兰素史克知识产权开发有限公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3612536-B1 | OXEPINOPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3-KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-12-15 | — | — | EP | disclosed |
| CN-108884046-B | Chemical compounds as inhibitors of kinase activity | 葛兰素史克知识产权开发有限公司 | 2021-11-09 | — | — | CN | disclosed |
| WO-2021191875-A1 | CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-09-30 | — | — | WO | disclosed |
| EP-1962932-B1 | MEDICAMENT DISPENSER | GLAXO GROUP LTD (GB) | 2021-09-08 | — | — | EP | disclosed |
| CN-108570048-B | Substituted heteroaryl compounds, compositions and uses thereof | 广东东阳光药业有限公司 | 2021-06-08 | — | — | CN | disclosed |
| WO-2006108699-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| CN-1845933-A | Specific glucocorticosteroid compounds with anti-inflammatory activity | GLAXO GROUP LTD (GB) | 2006-10-11 | — | — | CN | disclosed |
| WO-2006090142-A1 | l-{4- [ (l-CYCLOBUTYL-4-PIPERIDINYL) OXY] PHENYL] -4-{ [4- (METHYLSULFONYL) PHENYL]CARBONYL PIPERAZINE AS HISTAMINE H3 ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006072600-A1 | ANDROSTANE 17-ALPHA-CARBONATE FOR USE IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC CONDITIONS | GLAXO GROUP LIMITED (GB) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006072599-A2 | ANDROSTANE 17-ALPHA CARBONATE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC AND INFLAMMATORY CONDITIONS | GLAXO GROUP LIMITED (GB) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006015870-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006003407-A2 | CHIMERIC AND HUMANISED MONOCLONAL ANTIBODIES AGAINST INTELEUKIN- 13 | GLAXO GROUP LIMITED (GB) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006000401-A1 | SUBSTITUTED OXAZINES AS GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| WO-2006000398-A1 | 2,3-BENZOXAZIN DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005116037-A1 | PURINE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066037-A1 | CATHEPSIN INHIBITORS FOR PREVENTING OR TREATING VIRAL INFECTIONS | CTSV, CTSS, CTSA | CHRM2 4864/4885CHRM1 4836/4885CACNA1C 3514/4885 |
| US-11555040-B2 | Oxepinopyrazole derivatives as inhibitors of P13-kinase activity | CDK3, CDK13, AKT3 | CHRM2 1917/4885CHRM1 1223/4885CACNA1C 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.